Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: notyet who wrote (28522)	3/13/1999 9:45:00 AM
From: aknahow	Respond to of 32384

Here is the link. "Distinguishing between "no evidence of effect" and "evidence of no effect" in randomised controlled trials and other comparison" archdischild.com I did not want to mention XOMA to avoid getting people off the track but of course I should have since what I am trying to determine is something several of us have been asking. Has this been done before? And if it has what was the eventual history of the trials? Unfortunatly when XOMA is introduced, some people go crazy, either because they think one is attacking it or hyping it. The question about a pre established mortality rate in both arms is interesting enough and does not need to be attached to any specific company.